Am J Transplant, Volume 19, Suppl 3 Archives - Page 45 of 214 - ATC Abstracts

2019 American Transplant Congress
Yellow Fever and Renal Transplantation: Influence of Vaccination and Infection on the Emergence of Antibody-Mediated Rejection
M. V. Sousa¹, R. L. Zollner², R. S. Stucchi³, I. F. Boin⁴, E. C. Ataide⁴, M. Mazzali¹
¹Department of Internal Medicine - Division of Nephrology, University of Campinas, Campinas, Brazil, ²Department of Internal Medicine, University of Campinas, Campinas, Brazil, ³Department of Internal Medicine - Division of Infectious Diseases, University of Campinas, Campinas, Brazil, ⁴Surgery Department, University of Campinas, Campinas, Brazil
*Purpose: Yellow fever (YF) is a viral hemorrhagic disease transmitted by mosquitos, with variable clinical disease manifestations from a mild, undifferentiated febrile illness to severe…
2019 American Transplant Congress
Do Outcomes Differ in Glomerulitis Predominant Antibody Mediated Rejection and Peritubular capillaritis Predominant Antibody Mediated Rejection?
S. Sethi¹, J. Hou², M. Lin², Y. Ren², A. Peng¹, R. Najjar¹, A. Vo¹, S. Jordan¹, M. Haas², E. Huang¹
¹Comprehensive Transplant Center, Cedars Sinai Medical Center, Los Angeles, CA, ²Pathology, Cedars Sinai Medical Center, Los Angeles, CA
*Purpose: The diagnosis of antibody-mediated rejection (ABMR) in renal allografts requires microvascular inflammation in the form of glomerulitis or peritubular capillaritis (g>0 and/or ptc>0). We…
2019 American Transplant Congress
Clinical Presentation After Hepatitis B Recurrence In Liver Transplant Patients
W. Lee, C. Cheng, T. Wu, Y. Wang, C. Lee, T. Wu, H. Chou, K. Chan
Chang-Gung Hospital, Taoyuan, Taiwan
*Purpose: Combination of anti-hepatitis B immunoglobulin and antiviral agents is the standard care for prophylaxis of hepatitis B virus (HBV) recurrence after liver transplantation. However,…
2019 American Transplant Congress
Gene Expression Profiles in CD8+ T Cells in Chronic Antibody-Mediated Rejection (CAMR) of Kidney Transplantation
P. Pontrelli¹, F. Rascio², M. Accetturo¹, G. Castellano¹, S. Simone¹, G. Stallone², L. Gesualdo¹, G. Grandaliano²
¹Department of Emergency, and Organ Transplantation, Nephrology, Dialysis and Transplantation Unit, University of Bari, Bari, Italy, ²Dept. of Surgical and Medical Sciences, Nephrology Unit, University of Foggia, Foggia, Italy
*Purpose: CAMR is the main cause of chronic graft injury and subsequent graft loss. Most of the studies on the subject focused their attention to…
2019 American Transplant Congress
EBV⁺ PTLD Cell Lines Secrete Exosomes Containing microRNAs That Alter Immune Responses
S. Syed, E. Maloney, A. Hui, O. Martinez, S. Krams
Stanford Univ School of Med, Stanford, CA
*Purpose: Exosomes are nanometric (50-150nm) membrane vesicles that are released, into blood and other body fluids, by most cell types. Exosomes, which are generated from…
2019 American Transplant Congress
Modeling Multiple Registrations and the Impact at the National and Regional Scale
C. Harvey, R. Weigel
Computational Science and Informatics, George Mason University, Fairfax, VA
*Purpose: Current policies in the U.S. allow patients to register at multiple organ donor service areas (DSAs), provided they have physician approval and can cover…
2019 American Transplant Congress
Kidney Transplantation after Sleeve Gastrectomy in the Morbidly Obese Candidate: Results of a Five-Year Experience
Y. Kim, A. J. Bailey, M. C. Morris, J. Hlavaty, M. C. Cuffy, E. S. Woodle, S. A. Shah, T. S. Diwan
Department of Surgery, University of Cincinnati, Cincinnati, OH
*Purpose: Morbid obesity serves as a barrier to kidney transplantation (KT) due to potential suboptimal post-transplant outcomes. Laparoscopic sleeve gastrectomy (LSG) has previously been shown…
2019 American Transplant Congress
Gut Microbiota May Affect a Variability of Tacrolimus Trough Levels in Kidney Transplant Recipients
J. Kim¹, H. Cho², J. Park³, M. Kwak⁴, B. Kim⁴, J. Lee⁵, D. Kim¹, B. Kim⁶, Y. Kim¹, H. Lee¹
¹Seoul National University Hospital, Seoul, Korea, Republic of, ²Chungbuk National University Hospital, Cheongju, Korea, Republic of, ³Kangwon National University Hospital, Chuncheon, Korea, Republic of, ⁴Chunlab Inc., Seoul, Korea, Republic of, ⁵Seoul National University Boramae Hospital, Seoul, Korea, Republic of, ⁶Hallym University, Chuncheon, Korea, Republic of
*Purpose: The gut microbiota alters expression of drug-metabolizing enzymes and transporters, and consequently affects therapeutic dose and response of medicines. We aimed to investigate the…
2019 American Transplant Congress
Specific Reasons for Public Health Service (PHS) Increased Risk (IR) Designation Had Little Influence on Doctors’ Kidney Offer Acceptance Decisions in Controlled “Lab” Experiment
D. Stewart¹, J. Rosendale¹, H. McGehee¹, J. Schold², J. Lindemans³, J. Kessler⁴, C. Sullivan⁴, K. Mekeel⁵, R. Stratta⁶, R. Formica⁷, D. Klassen¹
¹UNOS, Richmond, VA, ²CCF, Cleveland, OH, ³Duke, Durham, NC, ⁴Wharton, Philadelphia, PA, ⁵UCSD, San Diego, CA, ⁶Wake Forest, Winston-Salem, NC, ⁷Yale, New Haven, CT
*Purpose: Over 25% of donors are labeled as PHS “increased risk,” a designation associated with reduced organ utilization despite favorable risk/benefit calculations for most patients.…
2019 American Transplant Congress
Renal Function between Tenofovir and Entecavir in Post-Liver Transplanted Hepatitis B Patients
S. Kim, J. Kim, S. Lee, J. Rhu, Y. Chung, S. Kim, J. Joh, S. Lee, G. Choi, J. Park, S. Lee, K. Lee
Transplantation, Samsung Medical Center, Seoul, Korea, Republic of
*Purpose: Tenofovir, Nucleotide analogue polymerase inhibitor is already accepted as effective and tolerable drug for treatment of hepatitis B virus (HBV) as much as entecavir.…